4.7 Editorial Material

Targeting vulnerabilities of adult T-cell leukemia

Related references

Note: Only part of the references are listed.
Article Hematology

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Takashi Ishio et al.

Summary: The study identifies CDK6 as a novel therapeutic target for adult T-cell leukemia/lymphoma (ATLL) and suggests the potential of combining CDK6 inhibitor palbociclib with mTORC1 inhibitors for treating this difficult malignancy.

BLOOD (2022)

Article Medicine, Research & Experimental

IRF4 instructs effector Treg differentiation and immune suppression in human cancer

Giorgia Alvisi et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Article Multidisciplinary Sciences

HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling

Yusuke Higuchi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Multidisciplinary Sciences

JunB regulates homeostasis and suppressive functions of effector regulatory T cells

Shin-ichi Koizumi et al.

NATURE COMMUNICATIONS (2018)

Review Biology

Human T-cell leukaemia virus type 1: parasitism and pathogenesis

Charles R. M. Bangham et al.

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2017)

Article Microbiology

HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo

Yorifumi Satou et al.

PLOS PATHOGENS (2011)